☆ 4.7 Letter

Antibodies to domain I of β-2-glycoprotein I and IgA antiphospholipid antibodies in patients with 'seronegative' antiphospholipid syndrome

ANNALS OF THE RHEUMATIC DISEASES (2015)

Journal

ANNALS OF THE RHEUMATIC DISEASES

Volume 74, Issue 1, Pages 317-U444

Publisher

BMJ PUBLISHING GROUP

DOI: 10.1136/annrheumdis-2014-206483

Keywords

-

Categories

Rheumatology

Funding

Arthritis Research UK [19423, 20164] Funding Source: Medline
Versus Arthritis [19423] Funding Source: Medline
Rosetrees Trust [M281] Funding Source: researchfish
Versus Arthritis [19423] Funding Source: researchfish

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Immunology

PEGylated Domain I of Beta-2-Glycoprotein I Inhibits Thrombosis in a Chronic Mouse Model of the Antiphospholipid Syndrome

Rohan Willis, Thomas C. R. McDonnell, Charis Pericleous, Emilio B. Gonzalez, Alvaro Schleh, Zurina Romay-Penabad, Ian P. Giles, Anisur Rahman

Summary: Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by vascular thrombosis and pregnancy morbidity. The current treatment options have limitations, and there is a need for more targeted therapies. Researchers developed a modified protein variant using site-specific chemical addition of polyethylene glycol (PEG), which effectively inhibited thrombus formation caused by pathogenic antibodies. These findings provide further evidence supporting the potential efficacy of PEG-modified protein as a treatment option for APS.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Biochemistry & Molecular Biology

IgA Antiphospholipid Antibodies in Antiphospholipid Syndrome and Systemic Lupus Erythematosus

Tatiana Reshetnyak, Fariza Cheldieva, Maria Cherkasova, Alexander Lila, Evgeny Nasonov

Summary: This study investigates the role of IgA antibodies to cardiolipin (aCL) and IgA antibodies to beta-2 glycoprotein 1 (anti-beta(2)-GP1) in the development of vascular complications in patients with antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE). The results show that the levels of IgA aCL and IgA anti-beta(2)-GP1 are significantly higher in APS patients compared to SLE patients and the control group. These antibodies are closely associated with thrombosis in APS, demonstrating high specificity but low sensitivity for the diagnosis of APS.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Article Immunology

Interaction of the antiphospholipid syndrome autoantigen beta-2 glycoprotein I with DNA and neutrophil extracellular traps

Katarina Kmet'ova, Elena Lonina, Srilakshmi Yalavarthi, Jerrold S. Levine, Claire K. Hoy, Cyrus Sarosh, Kelsey Gockman, Alexandra E. Morris, Ajay Tambralli, Jacqueline A. Madison, Yu Zuo, Rebecca Subang, Joyce Rauch, Jason S. Knight

Summary: β2GPI can bind not only to phospholipids, but also to cell-free DNA and neutrophil extracellular traps (NETs). The study showed that β2GPI interacts with cell-free DNA and NETs in a dose-dependent manner, retarding their migration. The authors also demonstrated the presence of β2GPI-DNA complexes in the plasma of APS patients, suggesting a potential role of this interaction in autoimmunity.

CLINICAL IMMUNOLOGY (2023)

Add to Collection

Review Hematology

A systematic review of the association between anti-β-2 glycoprotein I antibodies and APS manifestations

Debbie Jiang, Wendy Lim, Mark Crowther, David Garcia

Summary: The presence of anti-B2GPI is weakly associated with thrombosis and inconsistently associated with obstetric complications, with very low-quality evidence and study heterogeneity preventing a quantitative assessment.

BLOOD ADVANCES (2021)

Add to Collection

Article Rheumatology

Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset

Marwa Elkhalifa, Ana-Maria Orbai, Laurence S. Magder, Michelle Petri, Graciela S. Alarcon, Caroline Gordon, Joan Merrill, Paul R. Fortin, Ian N. Bruce, David Isenberg, Daniel Wallace, Ola Nived, Rosalind Ramsey-Goldman, Sang-Cheol Bae, John G. Hanly, Jorge Sanchez-Guerrero, Ann E. Clarke, Cynthia Aranow, Susan Manzi, Murray Urowitz, Dafna D. Gladman, Ken Kalunian, Victoria P. Werth, Asad Zoma, Sasha Bernatsky, Munther Khamashta, Soren Jacobsen, Jill P. Buyon, Mary Anne Dooley, Ronald van Vollenhoven, Ellen Ginzler, Thomas Stoll, Christine Peschken, Joseph L. Jorizzo, Jeffery P. Callen, Sam Lim, Murat Inanc, Diane L. Kamen, Anisur Rahman, Kristjan Steinsson, Andrew G. Franks

Summary: The study assessed the prevalence of anti-beta 2 glycoprotein I IgA in SLE compared to other rheumatic diseases and its association with disease manifestations. Results showed that anti-beta 2 glycoprotein I IgA is more common in patients with SLE, particularly in those of African descent.

LUPUS (2021)

Add to Collection

Article Medical Laboratory Technology

Frequency of serological markers of rheumatoid arthritis in patients with IgA anti-β2 glycoprotein I antibodies

Sarra Melayah, Mariem Ghozzi, Amani Mankai, Fatma Mechi, Ibtissem Ghedira

Summary: This study found that the frequencies of CCP-Ab and RF are high in patients with IgA isotype of anti-beta 2 glycoprotein I antibodies, suggesting that these patients are susceptible to developing RA.

JOURNAL OF CLINICAL LABORATORY ANALYSIS (2022)

Add to Collection

Article Rheumatology

Carbamylation of β2-glycoprotein I generates new autoantigens for antiphospholipid syndrome: a new tool for diagnosis of 'seronegative' patients

Antonella Capozzi, Simona Truglia, Brigitta Buttari, Serena Recalchi, Gloria Riitano, Valeria Manganelli, Silvia Mancuso, Cristiano Alessandri, Agostina Longo, Vincenzo Mattei, Elisabetta Profumo, Tina Garofalo, Roberta Misasi, Fabrizio Conti, Maurizio Sorice

Summary: The study identifies Carb-beta(2)-GPI as a new autoantigen in APS, which may be a significant marker for SN-APS patients.

RHEUMATOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Evidence of Thrombogenesis Recurrence Induced by IgA Antiphospholipid Antibody β2 Glycoprotein I-Dependent in Early Adulthood

Mirna S. Yacoub, Justin Khine, Ali Najar, Sri Yadlapalli

Summary: The pathogenesis of antiphospholipid syndrome (APS) involves the action of antiphospholipid antibodies (aPLs) against Beta-2 glycoprotein-I (beta(2)GPI). The association of IgA isotypes with APS and thrombosis is controversial.

CUREUS JOURNAL OF MEDICAL SCIENCE (2022)

Add to Collection

Article Medical Laboratory Technology

Anticardiolipin and anti-beta 2-glycoprotein I antibodies in patients with unexplained articular manifestations

Sarra Melayah, Mariem Ghozzi, Ibtissem Ghedira, Amani Mankai

Summary: This study found that antiphospholipid antibodies (aPL) were common in patients with articular manifestations, mainly directed against beta(2)GPI. However, the role of these antibodies remains to be specified.

JOURNAL OF CLINICAL LABORATORY ANALYSIS (2023)

Add to Collection

Review Immunology

Effects of anti-beta 2-glycoprotein 1 antibodies and its association with pregnancy-related morbidity in antiphospholipid syndrome

Juan J. Fierro, Manuela Velasquez, Angela P. Cadavid, Karina de Leeuw

Summary: Antiphospholipid syndrome (APS) is an autoimmune disease characterized by thrombosis and pregnancy-related complications, associated with persistent positivity of antiphospholipid antibodies (aPL). Antibodies against ss2GP1 (ass2GP1) play a crucial role in the pathogenesis of APS and may be used for obstetric risk stratification. Targeted therapies aimed at ss2GP1 could potentially prevent pregnancy morbidity in APS.

AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Presence of Extra-Criteria Antiphospholipid Antibodies Is an Independent Risk Factor for Ischemic

Laura Naranjo, Fernando Ostos, Francisco Javier Gil-Etayo, Jesus Hernandez-Gallego, Oscar Cabrera-Marante, Daniel Enrique Pleguezuelo, Raquel Diaz-Simon, Mercedes Cerro, David Lora, Antonio Martinez-Salio, Antonio Serrano

Summary: This study evaluated the prevalence of aPL (antiphospholipid antibodies) in ischemic stroke patients and identified IgA aB2GPI as an independent risk factor for ischemic stroke. The results showed that dyslipidemia, arterial hypertension, atrial fibrillation, and smoking were independent risk factors for ischemic stroke within the cardiovascular risk factors.

FRONTIERS IN CARDIOVASCULAR MEDICINE (2021)

Add to Collection

Article Hematology

Plasminogen activator-coated nanobubbles targeting cell- bound & beta; 2-glycoprotein I as a novel thrombus-specific thrombolytic strategy

Paolo Macor, Paolo Durigutto, Monica Argenziano, Kate Smith-Jackson, Sara Capolla, Valeria Di Leonardo, Kevin Marchbank, Valerio Stefano Tolva, Fabrizio Semeraro, Concetta T. Ammollo, Mario Colucci, Roberta Cavalli, Pierluigi Meroni, Francesco Tedesco

Summary: A new targeted thrombolytic agent consisting of nanobubbles coated with recombinant tissue plasminogen activator (rtPA) and a recombinant antibody specific for cell-bound 132-GPI was developed. The targeted nanobubbles exhibited greater lysing capabilities for platelet-rich blood clots and induced rapid and persistent recanalization of occluded vessels in animal models. This study suggests that targeting cell-bound 132-GPI may be an effective and thrombus-specific thrombolytic strategy.

HAEMATOLOGICA (2023)

Add to Collection

Review Pharmacology & Pharmacy

Treatment of Refractory/High-Risk Pregnancies With Antiphospholipid Syndrome: A Systematic Review of the Literature

Ariela Hoxha, Daniela Tormene, Elena Campello, Paolo Simioni

Summary: This study conducted a systematic review on the additional treatments used in refractory and high-risk antiphospholipid antibody syndrome (APS) pregnancies. The results showed that combination therapy with IVIG and PEX achieved a 100% live birth rate in refractory APS pregnancies, while Pravastatin, IA, and PEX showed higher live birth rates in high-risk APS pregnancies.

FRONTIERS IN PHARMACOLOGY (2022)

Add to Collection

Article Rheumatology

2023 ACR/EULAR antiphospholipid syndrome classification criteria

Medha Barbhaiya, Stephane Zuily, Ray Naden, Alison Hendry, Florian Manneville, Mary-Carmen Amigo, Zahir Amoura, Danieli Andrade, Laura Andreoli, Bahar Artim-Esen, Tatsuya Atsumi, Tadej Avcin, Michael H. Belmont, Maria Laura Bertolaccini, D. Ware Branch, Graziela Carvalheiras, Alessandro Casini, Ricard Cervera, Hannah Cohen, Nathalie Costedoat-Chalumeau, Mark Crowther, Guilherme de Jesus, Aurelien Delluc, Sheetal Desai, Maria De Sancho, Katrien M. Devreese, Reyhan Diz-Kucukkaya, Ali Duarte-Garcia, Camille Frances, David Garcia, Jean-Christophe Gris, Natasha Jordan, Rebecca K. Leaf, Nina Kello, Jason S. Knight, Carl Laskin, Alfred I. Lee, Kimberly Legault, Steve R. Levine, Roger A. Levy, Maarten Limper, Michael D. Lockshin, Karoline Mayer-Pickel, Jack Musial, Pier Luigi Meroni, Giovanni Orsolini, Thomas L. Ortel, Vittorio Pengo, Michelle Petri, Guillermo Pons-Estel, Jose A. Gomez-Puerta, Quentin Raimboug, Robert Roubey, Giovanni Sanna, Surya V. Seshan, Savino Sciascia, Maria G. Tektonidou, Angela Tincani, Denis Wahl, Rohan Willis, Cecile Yelnik, Catherine Zuily, Francis Guillemin, Karen Costenbader, Doruk Erkan

Summary: This study developed new APS classification criteria with high specificity, including clinical and laboratory domains, and improved classification accuracy through weighting and stratification.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Add to Collection

Review Immunology

An advanced understanding of the heterogeneous clinical features of non-criteria obstetric antiphospholipid syndrome: Two case reports and a literature review

Xue Peng, Xi Tan, Aiyun Xing

Summary: Antiphospholipid syndrome (APS) is an acquired autoimmune disorder characterized by recurrent thrombosis and pregnancy complications. Obstetrical APS (OAPS) specifically refers to APS in pregnant women. The classification criteria for OAPS have generated discussion due to the possibility of excluding certain patients. This article presents two cases of non-criteria OAPS with severe complications and discusses the diagnosis, treatment, and prognosis of this unusual antenatal event. It also provides an overview of the pathogenetic mechanisms and clinical features of OAPS.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection

Letter Clinical Neurology

Clinical and biological features of cerebral venous sinus thrombosis following ChAdOx1 nCov-19 vaccination

Christina Crossette-Thambiah, Charis Pericleous, Namir Asmar, Joshua Bomsztyk, Amita Ranger, Abdul Shlebak, Saipriya Ramji, Soma Banerjee, Mike Laffan, Deepa Arachchillage

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2022)

Add to Collection

Article Respiratory System

Inhaled corticosteroids reduce senescence in endothelial progenitor cells from patients with COPD

Koralia Paschalaki, Christos Rossios, Charis Pericleous, Mairi MacLeod, Stephen Rothery, Gavin C. Donaldson, Jadwiga A. Wedzicha, Vassilis Gorgoulis, Anna M. Randi, Peter J. Barnes

Summary: Cellular senescence is accelerated in smokers and COPD patients. In COPD patients on inhaled corticosteroids, cellular senescence and DNA damage response are reduced. In vitro studies suggest that corticosteroids protect endothelial cells by reducing oxidative stress-induced senescence and apoptosis.

THORAX (2022)

Add to Collection

Article Rheumatology

Autoimmune disease and COVID-19: a multicentre observational study in the United Kingdom

Deepa J. Arachchillage, Indika Rajakaruna, Charis Pericleous, Philip L. R. Nicolson, Mike Makris, Mike Laffan

Summary: Patients with autoimmune disease (AD) admitted with COVID-19 showed differences in laboratory findings and clinical outcomes compared to patients without AD. Those with severe rheumatologic AD had higher mortality rates and elevated levels of anemia, renal impairment, LDH, CRP, which are associated with increased mortality in COVID-19 patients.

RHEUMATOLOGY (2022)

Add to Collection

Article Immunology

PEGylated Domain I of Beta-2-Glycoprotein I Inhibits Thrombosis in a Chronic Mouse Model of the Antiphospholipid Syndrome

Rohan Willis, Thomas C. R. McDonnell, Charis Pericleous, Emilio B. Gonzalez, Alvaro Schleh, Zurina Romay-Penabad, Ian P. Giles, Anisur Rahman

Summary: Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by vascular thrombosis and pregnancy morbidity. The current treatment options have limitations, and there is a need for more targeted therapies. Researchers developed a modified protein variant using site-specific chemical addition of polyethylene glycol (PEG), which effectively inhibited thrombus formation caused by pathogenic antibodies. These findings provide further evidence supporting the potential efficacy of PEG-modified protein as a treatment option for APS.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Rheumatology

Outcomes of children born to mothers with systemic lupus erythematosus exposed to hydroxychloroquine or azathioprine

John A. Reynolds, Mary Gayed, Munther A. Khamashta, Francesca Leone, Veronica Toescu, Ian N. Bruce, Ian Giles, Lee-Suan Teh, Neil McHugh, Mohammed Akil, Christopher J. Edwards, Caroline Gordon

Summary: This study investigated the outcomes of children born to mothers with SLE exposed to HCQ or AZA during pregnancy. The results showed that there were no significant negative outcomes in children exposed to HCQ during pregnancy. However, the use of AZA was associated with an increased reporting of childhood infection, which requires further study.

RHEUMATOLOGY (2023)

Add to Collection

Review Rheumatology

Risk of adverse pregnancy outcomes prior to the onset of an autoimmune rheumatic disease: a systematic review

Candido Munoz Munoz, Bethan Goulden, Kawser Ahmed, Jaume Alijotas-Reig, Ian Giles

Summary: Women with autoimmune rheumatic diseases (ARD) have an increased risk of adverse pregnancy outcomes. This risk also exists in women with preclinical ARD (pre-ARD) before they are diagnosed with ARD.

RHEUMATOLOGY (2023)

Add to Collection

Article Rheumatology

Antiphospholipid antibody positivity in early systemic lupus erythematosus is associated with subsequent vascular events

Nicola Farina, Ruya Abdulsalam, Thomas McDonnell, Charis Pericleous, Amrita D'Souza, Vera M. Ripoll, Jemma Webster, David A. Isenberg, Ian Giles, Anisur Rahman

Summary: Double/triple-positivity for IgG anti-CL, anti-beta 2GPI and anti-DI in early SLE identifies a population at higher risk of subsequent VE.

RHEUMATOLOGY (2023)

Add to Collection

Article Rheumatology

British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids

Mark D. Russell, Mrinalini Dey, Julia Flint, Philippa Davie, Alexander Allen, Amy Crossley, Margreta Frishman, Mary Gayed, Kenneth Hodson, Munther Khamashta, Louise Moore, Sonia Panchal, Madeleine Piper, Clare Reid, Katherine Saxby, Karen Schreiber, Naz Senvar, Sofia Tosounidou, Maud van de Venne, Louise Warburton, David Williams, Chee-Seng Yee, Caroline Gordon, Ian Giles

RHEUMATOLOGY (2023)

Add to Collection

Article Hematology

Frequency and Clinical Significance Anti-PS/PT Antibodies in Patients with Antiphospholipid Syndrome - Single Centre Observational Study in the United Kingdom

Hithin Noble, Christina Crossette-Thambiah, Zain Odho, Nilanthi Karawitage, Karen Logan, Charis Pericleous, Mike Laffan, Deepa J. Arachchillage

SEMINARS IN THROMBOSIS AND HEMOSTASIS (2023)

Add to Collection

Article Rheumatology

Antibodies to FXa and thrombin in patients with SLE differentially regulate C3 and C5 cleavage

Thomas McDonnell, Raj Amarnani, Carina Spicer, Hajar Jbari, Charis Pericleous, Valentina A. Spiteri, Chris Wincup, Bahar Artim-Esen, Ian Mackie, Marina Botto, Anisur Rahman, Ian Giles

Summary: The significance of antibodies directed against activated factor X (FXa) and thrombin (Thr) in patients with SLE and/or antiphospholipid syndrome (APS) is unknown. This study found that aThr IgG increased Thr-mediated activation of C3 and C5, while aFXa IgG did not increase C3 or C5 activation. Structural analysis suggested that aFXa IgG may have a higher likelihood of steric hindrance on FXa compared to the AT-Thr-aThr IgG complex. Although there was no significant association between positivity for aFXa or aTHr IgG and C3 levels or disease activity, there was a trend for patients positive for aFXa IgG alone or both aFXa and aThr IgG to have lower levels of C3.

LUPUS SCIENCE & MEDICINE (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Hydroxychloroquine as an Immunomodulatory and Antithrombotic Treatment in Antiphospholipid Syndrome

Deepa J. Arachchillage, Mike Laffan, Charis Pericleous

Summary: Antiphospholipid syndrome (APS) is a highly prothrombotic disorder caused by thrombo-inflammatory antiphospholipid antibodies (aPL) that lead to thrombosis through various mechanisms. Obstetric complications in APS are a result of placental thrombosis, inflammation, and complement activation. While anticoagulation is the main treatment, it may not effectively prevent thrombosis recurrence in some patients, especially those with triple positive aPL.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Somatostatin Receptor PET/MR Imaging of Inflammation in Patients With Large Vessel Vasculitis and Atherosclerosis

Andrej Corovic, Christopher Wall, Meritxell Nus, Deepa Gopalan, Yuan Huang, Maria Imaz, Michal Zulcinski, Marta Peverelli, Anna Uryga, Jordi Lambert, Dario Bressan, Robert T. Maughan, Charis Pericleous, Suraiya Dubash, Natasha Jordan, David R. Jayne, Stephen P. Hoole, Patrick A. Calvert, Andrew F. Dean, Doris Rassl, Tara Barwick, Mark Iles, Mattia Frontini, Greg Hannon, Roido Manavaki, Tim D. Fryer, Luigi Aloj, Martin J. Graves, Fiona J. Gilbert, Marc R. Dweck, David E. Newby, Zahi A. Fayad, Gary Reynolds, Ann W. Morgan, Eric O. Aboagye, Anthony P. Davenport, Helle F. Jorgensen, Ziad Mallat, Martin R. Bennett, James E. Peters, James H. F. Rudd, Justin C. Mason, Jason M. Tarkin

Summary: This study investigates the feasibility of using somatostatin receptor 2 (SST2) as a molecular imaging target for inflammation in large vessel vasculitis (LVV), and provides evidence for its potential in the diagnosis and therapeutic monitoring of LVV.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2023)

Add to Collection

Article Hematology

Evolution of Antiphospholipid Syndrome

Deepa J. Arachchillage, Charis Pericleous

Summary: Antiphospholipid syndrome (APS) is an autoimmune disease characterized by the presence of antiphospholipid antibodies, leading to thrombosis and/or pregnancy complications. APS has a long history dating back to the mid-20th century, when it was first identified during syphilis screening programs. While anticoagulation with vitamin K antagonists remains the main treatment for thrombotic APS, newer options like direct acting oral anticoagulants have shown inferiority, particularly in patients with triple-positive APS and arterial thrombosis. Immunomodulatory agents such as hydroxychloroquine are increasingly used to treat refractory cases of APS.

SEMINARS IN THROMBOSIS AND HEMOSTASIS (2023)

Add to Collection

Article Rheumatology

16th International congress on antiphospholipid antibodies task force report on antiphospholipid syndrome laboratory diagnostics and trends

Tatsuya Atsumi, Cecilia B. Chighizola, Yuichiro Fujieda, Ian Mackie, Massimo Radin, Robert Roubey, Maria Laura Bertolaccini

Summary: Classification criteria for antiphospholipid syndrome (APS) require specific antibodies to satisfy the laboratory disease definition, but there have been additional antibodies proposed in recent years. This article evaluates these new antibodies through the study and discussion of relevant data, and also discusses the testing of LA and the value of triple positivity.

LUPUS (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.